Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
ViroMissile, Inc.
MacroGenics
City of Hope Medical Center
University of Florida
University of Southern California
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
HiFiBiO Therapeutics
Seattle Children's Hospital
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
HiFiBiO Therapeutics
Actym Therapeutics, Inc.
Valo Therapeutics Oy
Guangzhou FineImmune Biotechnology Co., LTD.
Iovance Biotherapeutics, Inc.
Eli Lilly and Company
Centre Hospitalier Universitaire Vaudois
Y-mAbs Therapeutics
Xencor, Inc.
National Institutes of Health Clinical Center (CC)
Pfizer
DNAtrix, Inc.
National Cancer Institute (NCI)
Adaptimmune
Deciphera Pharmaceuticals, LLC
Sumitomo Pharma America, Inc.
Pfizer
Prelude Therapeutics
Quadriga Biosciences, Inc.
Genzada Pharmaceuticals USA, Inc.
Ludwig Institute for Cancer Research
MacroGenics
Pfizer
Seagen Inc.
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Celgene
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Tocagen Inc.
University of Chicago
National Institutes of Health Clinical Center (CC)
The Cleveland Clinic
M.D. Anderson Cancer Center
Virginia Commonwealth University
The Cleveland Clinic
City of Hope Medical Center
ImmunoFrontier, Inc.